Topivert Pharma Limited

Respivert Limited

Caldan Therapeutics Limited

Oxular Acquisitions Limited

Aaron Rigby

Stephen Thom

Matthew Colin Thor Fyfe

Thomas Matthew Baker

Gareth Harbottle

Vedran Hasimbegovic

Premji Meghani

Colin Peter Sambrook-Smith

Jane Theresa Brown

Trond Ulven

Don Smyth

Matjaz Brvar

Gerard Thomas

Bharat Shimpukade

Gavin Milne

Steffen V F Hansen

Stephen Connolly

Gareth William Harbottle

Novel tetrahydroisoquinoline and tetrahydrobenzazepine compounds of formula (I) capable of modulating the G-protein-coupled receptor GPR120, compositions comprising the compounds, and methods for their use for controlling insulin levels in vivo and for the treatment of conditions such as of diabetes, inflammation, obesity and metabolic diseases. 

Tetrahydro-benzo[d]azepine derivatives as GPR120 modulators

There are provided compounds of formula I, wherein Rto R, Rto R, L and Xto Xhave meanings given in the description, which compounds have antiinflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.

Kinase inhibitors

There are provided compounds of formula I, wherein R, R, Rto R, R, R, X, E and G have meanings given in the description, which compounds have antiinflammatory activity (e.g., through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.

Urea derivatives useful as kinase inhibitors

Growing community of inventors

Nottingham, United Kingdom

Aaron Rigby